Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
EMPLOYERS MUTUAL CASUALTY COMPANY et al v. CEPHALON, INC.
Case Number:
2:07-cv-04492
Court:
Nature of Suit:
Other Statutes: Other Statutory Actions
Multi Party Litigation:
Class Action
Judge:
Firms
- Cohen Placitella
- Freed Kanner
- Hagens Berman
- Kessler Topaz
- Kirkendall Dwyer
- Lowey Dannenberg
- Morgan Lewis
- Price Waicukauski
- Saltz Mongeluzzi
- Tucker Law Group
Companies
Sectors & Industries:
-
March 24, 2015
Class Cert. Denied In Cephalon Painkiller Marketing Suit
A Pennsylvania federal judge on Monday refused to certify a proposed class action accusing drugmaker Cephalon Inc. of unjustly enriching itself by marketing a painkiller for off-label uses, ruling the plaintiffs failed to show that a class action was the best way to resolve their claims.
-
July 24, 2013
Drug Buyers Urge Class Cert. In Cephalon Off-Label Use Suit
Two entities that pay for employees' prescription drugs on Wednesday asked a Pennsylvania federal judge to certify a class of other purchasers in a suit alleging that drug manufacturer Cephalon Inc. illegally pushed off-label uses for its painkiller Actiq.
-
October 30, 2012
Cephalon Faces Class Cert. Bid In Actiq Marketing Row
Two companies that chip in for employees' prescription drugs sought class certification last week in a Pennsylvania suit against Cephalon over off-label marketing for the painkiller Actiq, saying the fact that potentially hundreds of companies had to pay for workers' prescriptions made the case suitable for class treatment.
-
March 28, 2011
Cephalon Loses Bid For Quick Win In Marketing Suit
Cephalon Inc. lost a summary judgment bid Wednesday in a Pennsylvania class action claiming the company marketed the cancer pain management drug Actiq for off-label uses and caused third-party payors to pay hundreds of millions of dollars more for prescriptions.